RT Journal Article
SR Electronic
T1 Small-form-factor LED-based light application surface for indocyanine green-mediated antibacterial photothermal therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.08.20187161
DO 10.1101/2020.09.08.20187161
A1 Sakari Nikinmaa
A1 Niina Moilanen
A1 Timo Sorsa
A1 Juha Rantala
A1 Heikki Alapulli
A1 Anja Kotiranta
A1 Petri Auvinen
A1 Esko Kankuri
A1 Jukka Meurman
A1 Tommi Pätilä
YR 2020
UL http://medrxiv.org/content/early/2020/09/09/2020.09.08.20187161.abstract
AB We present here a small-form-factor LED-based antimicrobial photothermal therapy (aPTT) applicator surface, and its clinical feasibility as well as efficacy for administration of indocyanine green (ICG)-assisted aPTT to the dental plaque.Fifteen healthy adults were assigned to this four-day randomized study. After rinsing with ICG, 100J/cm2 of 810 nm light was applied to the aPTT-treatment area. Plaque area and gingival crevicular fluid (GCF) matrix metalloproteinase-8 (MMP-8) were measured, and plaque bacteriomes before and after the study were analyzed using 16S rRNA sequencing.aPTT administration was preformed successfully and plaque-specifically with the applicator surface. Total plaque area and endpoint MMP-8 levels were reduced on the aPTT-treatment side. aPTT reduced Streptococcus, Acinetobacteria, Capnocytophaga, and Rothia bacteria species in plaques. The applicator surface is feasible for aPTT self-administration, targets therapy to dental plaque, reduces plaque forming bacteria and exerts anti-inflammatory and –proteolytic effects.Competing Interest StatementT.P., S.N. and J.R. are co-founders in Koite Health Oy, a start-up company providing antibacterial photothermal solutions for dentistry.Clinical TrialISRCTN36318197Funding StatementThis research is part of a TUTL-project funded by Aalto University and Tekes (4364/31/2016).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of the Hospital District of Helsinki and Uusimaa (HUS/827/2018).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe 16S rRNA sequences are deposited to the Sequence Read Archive (SRA) of the National Center for Biotechnology Information (NCBI) under BioProject ID PRJNA661546. Additional requests for data should be addressed to the corresponding author Dr. Tommi Patila, tommi.patila{at}hus.fi